MarginsXMarginsX
Home › Markets › Health Care › MLYS

Mineralys Therapeutics Inc. (MLYS)

MLYS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.53
-5.22% on the day
Market cap
$1.3B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerMLYS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2023
SEC CIK0001933414
SEC industry codePharmaceutical Preparations
Incorporated inDELAWARE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
7.9 months
$101.3M cash at September 30, 2026
Share count, 1 year
+11.9%
2025-11-03 to 2026-10-29 · +115.4% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$78.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$101.3M cash; operating cash flow -$38.3M a quarter.Report 2026-09-30
Shares outstanding88,557,097 (2026-10-29); 79,139,956 a year earlier; 41,105,118 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Denver, Colorado, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $8.8M, sold $87.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$57.3M-$43.1M$101.3M$100KNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$241.1M-$32.6M$138.3M$100KNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$39.3M-$39.5M$112.8MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
Not filed-$32.2M-$37.9M$172.9MNo debt tagsNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$36.9M-$28.9M$217.6MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$43.3M-$30.2M$101.8MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$42.2M-$45.5M$165.0MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
Not filed-$48.9M-$66.8M$114.1MNo debt tagsNeeds four quarters10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-03
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-08

Source: SEC EDGAR submissions feed, 408 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week0.0%
1 month-27.0%
3 months-41.2%
Year to date-57.8%
1 year-65.4%
From 52-week high-65.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GHRSGH Research PLC$18.75-1.83%$1.3B
MNKDMannKind Corporation$3.96-4.24%$1.3B
INVAInnoviva Inc.$18.49-2.84%$1.3B
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
NKTRNektar Therapeutics$36.44-2.23%$1.2B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
AMPHAmphastar Pharmaceuticals Inc.$29.17-0.68%$1.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier